Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

  title={Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research},
  author={Sundeep Khosla and David B. Burr and Jane A. Cauley and David W Dempster and Peter R. Ebeling and Dieter Felsenberg and Robert F. Gagel and Vincente Gilsanz and Theresa A. Guise and Sreenivas Koka and Laurie K McCauley and Joan A McGowan and Marc D. McKee and Suresh Mohla and David G. Pendrys and Lawrence G. Raisz and Salvatore L. Ruggiero and David M. Shafer and Lillian Shum and Stuart L. Silverman and Catherine H Van Poznak and Nelson B. Watts and Sook-Bin Woo and Elizabeth Shane},
  journal={Journal of Bone and Mineral Research},
ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. This report summarizes the findings and recommendations of the task force. 

Bisphosphonates and osteonecrosis of the jaw: proceedings of an international conference

There has been an upsurge of multidisciplinary research since the adoption of a standardized definition of osteonecrosis of the jaw (ONJ) and the first bisphosphenate‐related ONJ conference in 2007 and this series of papers revisits topics presented at the conference.

Recent recommendations on bisphosphonate-associated osteonecrosis of the jaw.

Dentists should be able to recognize osteonecrosis of the jaw and how it is managed and bisphosphonates are now being used widely in the treatment of several conditions including osteoporosis, Paget's disease and metastatic malignancy.

The care and management of bisphosphonate--associated osteonecrosis of the jaw in the patient with multiple myeloma: a case study.

PURPOSE This is a case study of a patient with multiple myeloma presenting with bisphosphonate-associated osteonecrosis of the jaw after an extraction of tooth #18 while receiving intravenous

Osteonecrosis of the Jaw: Meeting Report from Skeletal Complications of Malignancy V: October 25-27, 2007 in Philadelphia, Pennsylvania, USA

Since the earliest case suggesting an association of osteonecrosis of the jaw (ONJ) with bisphosphonate (BP) use in 2003, many other ONJ cases have been documented, highlighting the need for

Current knowledge on bisphosphonate-related osteonecrosis of the jaws

A review of bisphosphonate-related osteonecrosis of the jaw, their uses, as well as their effects on the jaws is given.


A review of the literature regarding the epidemiology, pathophysiology, diagnostic studies, and several aspects related to prevention and treatment of osteonecrosis of the jaw.

Potential pathophysiological mechanisms in osteonecrosis of the jaw

Proposed mechanisms underlying ONJ development are explored and potential areas for future investigation are identified.



Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Adverse oral sequelae to bisphosphonate administration.

The clinical presentation, management, and proposed etiology of this adverse reaction are reviewed, and recommendations for identifying patients who may be at risk via medical history, present and past medications, specific drugs involved and recommended precautions involving various dental interventions are discussed.

Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates

Osteonecrosis of the mandible or maxilla associated with the use of bisphosphonates is a newly described entity never before discussed in the otolaryngology literature, and should be recognized early to avoid potential devastating consequences.

Osteonecrosis of the Jaw: More Research Needed

  • E. ShaneS. Goldring D. Pendrys
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2006
This editorial summarized the current evidence for an association between ONJ and bisphosphonates in doses used for osteoporosis and Paget’s disease and raised great concern among patients and health care professionals.

Bisphosphonates and osteonecrosis of the jaw.

This volumes seeks to improve awareness of the condition and the need for increased screening and improved diagnosis of ONJ and explores possible treatment options for ONJ to help guide future areas for research.

[Necrosis of the jaws under bisphosphonate therapy].

Presentation of three patients showing therapy-resistant osteonecrosis of the mandible under bisphosphonate medication provides more information on this clinically important side effect of oral bisph phosphate medication, also in osteoporosis therapy.

Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.

In MM pts the frequency of steroid treatment, parodonthopaties and anemia was particularly high, respectively 100%, 56%, and 56%, supporting the idea that these are additional risk factors for developing ONJ.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.

Prevention of BON is the best approach to management of this complication and existing protocols to manage the care of patients who will receive radiation therapy or chemotherapy may be used until specific guidelines for BON are developed.

Osteonecrosis of the jaw and bisphosphonates

100 years ago the manufacture of matches using yellow phosphorus was subject to an International Convention in Berne (1906), which resulted in substitution of yellow phosphorus for phosphorus